Heritage Trust Co Sells 18,136 Shares of Bristol Myers Squibb Company $BMY

Heritage Trust Co lessened its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 72.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,901 shares of the biopharmaceutical company’s stock after selling 18,136 shares during the period. Heritage Trust Co’s holdings in Bristol Myers Squibb were worth $372,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. increased its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares in the last quarter. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb during the 2nd quarter worth about $25,000. EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb during the 4th quarter worth about $32,000. Garner Asset Management Corp bought a new position in Bristol Myers Squibb during the 4th quarter worth about $35,000. Finally, Beacon Financial Strategies CORP bought a new position in Bristol Myers Squibb during the 4th quarter worth about $38,000. Institutional investors own 76.41% of the company’s stock.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.05% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on BMY shares. Wells Fargo & Company restated an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Bank of America decreased their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, April 9th. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Finally, Morgan Stanley restated an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $61.31.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb won expanded EU approval for Opdivo in combination with AVD as a frontline treatment for newly diagnosed advanced classical Hodgkin lymphoma, which could broaden use of one of its key cancer drugs. BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos
• Positive Sentiment: The FDA accepted Camzyos for priority review in adolescents with symptomatic obstructive hypertrophic cardiomyopathy, signaling a potential label expansion that could open a new patient population for the drug. FDA Accepts Camzyos Supplemental New Drug Application
• Positive Sentiment: Recent ASCO data highlighted progress in BMY’s late-stage pipeline, including mezigdomide and pumitamig, reinforcing the company’s growth story beyond legacy products. Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
• Neutral Sentiment: Unusual options activity showed traders buying a large number of call options, which can reflect speculation that more positive news could continue, but it does not by itself confirm a fundamental change.
• Negative Sentiment: Some commentary remains cautious, noting that BMY still faces patent-expiration headwinds through 2028 and that its stock may not be as cheap as it appears on traditional valuation measures. Why Bristol Myers Squibb Stock Isn’t Nearly As Cheap As It Looks

Bristol Myers Squibb Trading Down 1.1%

Bristol Myers Squibb stock opened at $54.34 on Wednesday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The stock has a market capitalization of $110.97 billion, a P/E ratio of 15.26, a PEG ratio of 0.16 and a beta of 0.24. The stock has a 50-day simple moving average of $58.25 and a 200 day simple moving average of $56.37.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. Bristol Myers Squibb’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.